Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease

Shoji, Kensuke; Funaki, Takanori; Yamada, Masaki; Mikami, Masashi; Miyake, Kozue; Ueno, Saki; Tao, Chiaki; Myojin, Shota; Aiba, Hiroyuki; Matsui, Toshihiro; Ogimi, Chikara; Kato, Hitoshi; Miyairi, Isao

doi:10.1016/j.jiac.2022.09.013

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,54) In previous pediatric cohort studies, most immunocompromised children and young adults had an appropriate humoral and cellular immune response, side effects were mild, and disease flare rates were low following COVID-19 vaccination. [55][56][57] This supports the need for a continuous emphasis on COVID-19 vaccination among the immunocompromised pediatric population, consistent with recommendations. 55,58,59) We also suggest that further studies examine the relationship between immunocompromised status and the risk of long COVID in children.…”

Section: Discussionsupporting

confidence: 73%

“…Studies have shown that COVID-19 vaccines (primarily mRNA vaccines) are effective against symptomatic COVID-19 among immunocompromised adult patients but lower than that in immunocompetent adults and varied considerably among subgroups.53,54) In previous pediatric cohort studies, most immunocompromised children and young adults had an appropriate humoral and cellular immune response, side effects were mild, and disease flare rates were low following COVID-19 vaccination [ 55 - 57 ]. This supports the need for a continuous emphasis on COVID-19 vaccination among the immunocompromised pediatric population, consistent with recommendations [ 55 , 58 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in immunocompromised children and adolescents

Kwak¹,

Eun²

2023

Clin Exp Pediatr

View full text Add to dashboard Cite

Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations, and continuous moni toring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted.

show abstract